Link Technologies, a manufacturer of oligonucleotide synthesis reagents, has appointed Michael McLean as chairman to lead it through a period of change and expansion
Link Technologies says it is actively seeking business partners to co-develop new products and commercialise and licence new research technologies.
McLean, currently CEO of Oligovax (France), said: "We welcome approaches from interested parties to discuss opportunities.
"Our chemistry expertise is a perfect match for life science companies working in diverse areas such as molecular diagnostics, microarrays and therapeutics.
Commenting on the appointment, Mike Gray, managing director of Link, said: "Mick is a very well respected and successful figure in the biotechnology industry.
"His expertise will be invaluable in helping us find and evaluate new opportunities for business development, both in our current DNA/RNA business and in adjacent market areas.
McLean added: "Link Technologies is a progressive company that has already established a reputation for quality products in the industry.
"I am delighted to be joining the company at this important period in its development and am looking forward to leading Link to even greater success".
McLean will be attending the Tides conference in Las Vegas (20-23 May 2007) along with John Bremner, business development director of Link Technologies.
